yingweiwo

Apoptosis

Apoptosis

Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.

There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.

Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.

Apoptosis related products

Structure Cat No. Product Name CAS No. Product Description
Dihydroartemisinin-d3 (Dihydroqinghaosu-d3; β-Dihydroartemisinin-d3; Artenimol-d3) V56270 Dihydroartemisinin-d3 (Dihydroqinghaosu-d3; β-Dihydroartemisinin-d3; Artenimol-d3) 176774-98-4 Dihydroartemisinin-d3 is the deuterium labelled form of Dihydroartemisinin.
DIM-C-PPHOH V3998 DIM-C-PPHOH 151358-47-3 DIM-C-pPhOH (also known as C-DIM8) is a Nur77 (NR4A1) antagonist.
Dinoprost-d4 (Prostaglandin F2a-d4; PGF2α-d4) V56430 Dinoprost-d4 (Prostaglandin F2a-d4; PGF2α-d4) 34210-11-2 Dinoprost-d4 is the deuterium labelled form of Dinoprost.
Diosbulbin D V52178 Diosbulbin D 66756-57-8 Diosbulbin D is a potentially hepatotoxic compound extracted from Dioscorea bulbifera L.
Diselaginellin B V83576 Diselaginellin B 1835299-12-1
Distamycin A (NSC-82150) V52176 Distamycin A (NSC-82150) 636-47-5 Distamycin A (NSC-82150), an oligopeptide antibiotic, is a minor groove binder that binds B-form DNA preferentially at A/T-rich sites.
Dithiodipropionic acid (3,3'-二硫代二丙酸) V52222 Dithiodipropionic acid (3,3'-dithiodipropionic acid) 1119-62-6 Dithiodipropionic acid can interact with CPUL1 (TrxR inhibitor) to form nanoaggregates (CPUL1-DA NAs).
DL-alpha-Tocopherol-d9 (DL-α-生育酚-d9) V56447 DL-alpha-Tocopherol-d9 (DL-alpha-Tocopherol-d9) 131230-17-6 DL-alpha-Tocopherol-d9 is the deuterated form of DL-alpha-Tocopherol.
DMU-212 V52171 DMU-212 134029-62-2 DMU-212 is a methylated analogue of resveratrol with anti-mitotic, antiproliferation, antioxidant and pro-apoptotic activities.
Docetaxel-d9 (RP-56976-d9) V52641 Docetaxel-d9 (RP-56976-d9) 940867-25-4 Docetaxel-d9 is the deuterium labelled form of Docetaxel.
Dopamine-d5 hydrochloride V56444 Dopamine-d5 hydrochloride 2193106-55-5 Dopamine-d5 ( HCl) is a deuterium labelled Dopamine ( HCl).
Dp44mT V1888 Dp44mT 152095-12-0 Dp44mT is a novel and potent iron chelator with DNA-damaging activity mediated by top2a inhibition and with selective antitumor activity.
DPP V54829 DPP 2668267-47-6 DPP is a platinum(IV) complex with pterostilbene-derived axial ligands.
DRAK1/2-IN-1 V54982 DRAK1/2-IN-1 1629227-34-4 DRAK1/2-IN-1 (compound 10e) is an active dual (bifunctional) inhibitor of DRAK1 and DRAK2 with Kds of 1 μM and 6 μM, respectively.
DRI-C21041 V52160 DRI-C21041 2101765-78-8 DRI-C21041 is a CD40/CD40L interaction inhibitor (antagonist) with IC50 of 0.31 μM.
DRI-C25441 V55015 DRI-C25441 2101765-83-5 DRI-C25441 is a potent blocker of CD40 and CD40L interaction with IC50 of 0.36 μM.
Drozitumab (PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody) V52159 Drozitumab (PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody) 912628-39-8 Drozitumab (PRO 95780) is a human agonistic monoclonal antibody (mAb) that binds to the death receptor DR5.
Dutasteride-13C6 (GG 745-13C6; GI 198745-13C6) V56432 Dutasteride-13C6 (GG 745-13C6; GI 198745-13C6) 1217685-27-2 Dutasteride-13C6 is the 13C (carbon 13)-labeled Dutasteride.
Duvakitug V55020 Duvakitug 2750005-84-4 Duvakitug is a human IgG1-λ2 monoclonal antibody (mAb) targeting TNFSF15/TL1A.
EAPB 02303 V53213 EAPB 02303 1958290-51-1 EAPB 02303 is a microtubule disruptor and inhibitor.
Contact Us